{{Drugbox
| verifiedrevid = 462089809
| IUPAC_name = 5-methyl-''N''-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide
| image = Leflunomide.svg
| image2 = Leflunomide ball-and-stick model.png
<!--Clinical data-->
| tradename = Arava, Arabloc, Lunava, Repso, Elafra
| Drugs.com = {{drugs.com|monograph|leflunomide}}
| MedlinePlus = a600032
| licence_EU = Arava
| licence_US = Leflunomide
| pregnancy_AU = X
| pregnancy_US = X
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral (tablets)
<!--Pharmacokinetic data-->
| bioavailability = 80%<ref name = MSR>{{cite web|title=Arava (leflunomide) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=11 March 2014|url=http://reference.medscape.com/drug/arava-leflunomide-343203#showall}}</ref>
| protein_bound = >99%<ref name = MSR/>
| metabolism = GI mucosa and liver<ref name = MSR/>
| elimination_half-life = 14–18 days<ref name = MSR/>
| excretion = Faeces (48%), urine (43%)<ref name = MSR/>
<!--Identifiers-->
| IUPHAR_ligand = 6825
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 75706-12-6
| ATC_prefix = L04
| ATC_suffix = AA13
| ATC_supplemental =  
| PubChem = 3899
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01097
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3762
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G162GK9U4W
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00749
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6402
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 960
<!--Chemical data-->
| C=12 | H=9 | F=3 | N=2 | O=2
| molecular_weight = 270.207 g/mol
| smiles = O=C(Nc1ccc(cc1)C(F)(F)F)c2c(onc2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VHOGYURTWQBHIL-UHFFFAOYSA-N
}}

'''Leflunomide''' (original brand name '''Arava''') is an immunosuppressive disease-modifying antirheumatic drug ([[DMARD]]),<ref name="pmid15271770">{{cite journal |vauthors=Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P |title=When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? |journal=Annals of the rheumatic diseases |volume=64 |issue=1 |pages=44–51 |date=January 2005 |pmid=15271770 |pmc=1755199 |doi=10.1136/ard.2003.016709 |url=http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=15271770}}</ref> used in active moderate-to-severe [[rheumatoid arthritis]] and [[psoriatic arthritis]]. It is a [[pyrimidine synthesis inhibitor]] that works by inhibiting [[dihydroorotate dehydrogenase]].<ref name="pmid17094333">{{cite journal |vauthors=Pinto P, Dougados M |title=Leflunomide in clinical practice |journal=Acta reumatológica portuguesa |volume=31 |issue=3 |pages=215–24 |year=2006 |pmid=17094333 |doi= |url=http://www.spreumatologia.pt/download_fich.php?path=pdfs&filename=ARP_2006_4_216_AR_-_Leflunomide.pdf}}</ref>

[[Image:Arava20mg.jpg|right|thumb|Bottle of Leflunomide (Arava) and tablet]]

==Medical use==
[[Rheumatoid arthritis]] and [[psoriatic arthritis]] are the only indications that have received regulatory approval.<ref name = MSR/><ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref> Arava was developed by Sanofi Aventis and approved by the U.S. Food and Drug Administration in 1998. Clinical studies regarding the following diseases have been conducted:<ref>http://clinicaltrials.gov/ct2/results?term=Leflunomide</ref> <!-- hide the obvious ", but these have to be reviewed critically, before approval can be given:" -->
<!-- may be more useful to group by the latest phase they have started or reported on -->
{{colbegin|3}}
* Polyoma [[BK virus]] [[Diabetic nephropathy|nephropathy]]<ref>{{cite journal|last=Blanckaert|first=K|author2=De Vriese, AS|title=Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients|journal=Nephrology Dialysis Transplantation|date=23 September 2006|volume=21|issue=12|pages=3364–3367|doi=10.1093/ndt/gfl404|url=http://ndt.oxfordjournals.org/content/21/12/3364.full.pdf|format=PDF|pmid=16998219}}</ref>
* [[Kimura's disease]]<ref>{{cite journal|last=Dai|first=L|author2=Wei, XN |author3=Zheng, DH |author4=Mo, YQ |author5=Pessler, F |author6= Zhang, BY |title=Effective treatment of Kimura's disease with leflunomide in combination with glucocorticoids.|journal=Clinical Rheumatology|date=June 2011|volume=30|issue=6|pages=859–65|doi=10.1007/s10067-011-1689-2|pmid=21286771}}</ref>
* [[Systemic lupus erythematosus]]<ref>{{cite journal|last=Wu|first=GC|author2=Xu, XD |author3=Huang, Q |author4= Wu, H |title=Leflunomide: friend or foe for systemic lupus erythematosus?|journal=Rheumatology International|date=February 2013|volume=33|issue=2|pages=273–6|doi=10.1007/s00296-012-2508-z|pmid=22961090}}</ref>
* [[Felty's syndrome]] <ref name="pmid12003373">{{cite journal |author1=Sanders, S |author2=Harisdangkul, V |title=Leflunomide for the treatment of rheumatoid arthritis and autoimmunity |journal=American Journal of the Medical Sciences |volume=323 |issue=4 |pages=190–3 |year=2002 |pmid=12003373 |doi= 10.1097/00000441-200204000-00004|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0002-9629&volume=323&issue=4&spage=190}}</ref>
* [[Takayasu arteritis]]<ref>{{cite journal|last=Unizony|first=S|author2=Stone, JH |author3=Stone, JR |title=New treatment strategies in large-vessel vasculitis.|journal=Current Opinion in Rheumatology|date=January 2013|volume=25|issue=1|pages=3–9|doi=10.1097/BOR.0b013e32835b133a|pmid=23114585|url=http://www.medscape.com/viewarticle/776095}}</ref>
* [[Granulomatosis with polyangiitis]]<ref name="pmid12003373" />
* [[Ankylosing spondylitis]]<ref>{{cite journal|last=Haibel|first=H|author2=Rudwaleit, M |author3=Braun, J |author4= Sieper, J |title=Six months open label trial of leflunomide in active ankylosing spondylitis.|journal=Annals of the Rheumatic Diseases|date=January 2005|volume=64|issue=1|pages=124–6|doi=10.1136/ard.2003.019174|pmid=15608310|url=http://ard.bmj.com/content/64/1/124.full.pdf|format=PDF|pmc=1755172}}</ref>
* [[Crohn's disease]]<ref>{{cite journal|last=Prajapati|first=DN|author2=Knox, JF |author3=Emmons, J |author4=Saeian, K |author5=Csuka, ME |author6= Binion, DG |title=Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy.|journal=Journal of Clinical Gastroenterology|date=August 2003|volume=37|issue=2|pages=125–8|pmid=12869881 |doi=10.1097/00004836-200308000-00006}}</ref><ref>{{cite journal|last=Holtmann|first=MH|author2=Gerts, AL |author3=Weinman, A |author4=Galle, PR |author5= Neurath, MF |title=Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety.|journal=Digestive Diseases and Sciences|date=April 2008|volume=53|issue=4|pages=1025–32|doi=10.1007/s10620-007-9953-7|pmid=17934840}}</ref>
* [[Sarcoidosis]]<ref>{{cite journal|last=Panselinas|first=E|author2=Judson, MA |title=Acute pulmonary exacerbations of sarcoidosis.|journal=Chest|date=October 2012|volume=142|issue=4|pages=827–36|doi=10.1378/chest.12-1060|pmid=23032450|url=http://journal.publications.chestnet.org/data/Journals/CHEST/25163/chest_142_4_827.pdf|format=PDF}}</ref>
* [[Uveitis]]<ref>{{cite journal|last=Roy|first=M|title=Early clinical experience with leflunomide in uveitis.|journal=Canadian Journal of Ophthalmology|date=August 2007|volume=42|issue=4|pages=634|pmid=17641721|doi=10.3129/canjophthalmol.i07-085}}</ref>
* [[Adult-onset Still's disease|Still's disease]]<ref>{{cite journal|last=Pirildar|first=T|title=Treatment of adult-onset Still's disease with leflunomide and chloroquine combination in two patients.|journal=Clinical Rheumatology|date=May 2003|volume=22|issue=2|pages=157|doi=10.1007/s10067-002-0667-0|pmid=12740686}}</ref>
* [[Prostate cancer]]<ref>{{cite web|title=Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer|url=http://clinicaltrials.gov/ct2/show/NCT00004071|work=ClinicalTrials.gov|publisher=National Institute of Health|date=September 2012|accessdate=11 March 2014}}</ref>
* [[Pemphigoid]]<ref>{{cite web|title=Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid (ARABUL)
| url=http://clinicaltrials.gov/ct2/show/NCT00802243|work=ClinicalTrials.gov|publisher=National Institute of Health|date=December 2008|accessdate=11 March 2014}}</ref>
* Prevention of organ transplant rejection<ref name = rh2010>{{cite journal|last=Teschner|first=S|author2=Burst, V |title=Leflunomide: a drug with a potential beyond rheumatology.|journal=Immunotherapy|date=September 2010|volume=2|issue=5|pages=637–50|doi=10.2217/imt.10.52|pmid=20874647}}</ref>
{{colend}}

==Side effects==
The dose-limiting side effects are liver damage, lung disease and immunosuppression.<ref name = rh2010/> The most common side effects (occurring in >1% of those treated with it) are, in approximately descending order of frequency:<ref name = MSR/><ref name = AMH/><ref name = TGA>{{cite web|title=PRODUCT INFORMATION ARAVA®|work=TGA eBusiness Services|publisher=sanofi-aventis australia pty ltd|date=7 August 2012|accessdate=11 March 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05926-3|format=PDF}}</ref><ref name = EMA>{{cite web|title=Arava : EPAR - Product Information|work=European Medicines Agency|publisher=Sanofi-Aventis Deutschland GmbH|date=21 November 2013|accessdate=11 March 2014|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000235/WC500026289.pdf|format=PDF}}</ref><ref name = MS>{{cite web|title=Data Sheet Arava®|work=Medsafe|publisher=sanofi-aventis new zealand limited|date=29 June 2012|accessdate=11 March 2014|url=http://www.medsafe.govt.nz/profs/datasheet/a/aravatab.pdf|format=PDF}}</ref><ref name = DM>{{cite web|title=ARAVA (leflunomide) tablet, film coated [sanofi-aventis U.S. LLC]|work=DailyMed|publisher=sanofi-aventis U.S. LLC|date=November 2012|accessdate=11 March 2014|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=320f63f2-fac3-4aee-aff8-85724e00ef52}}</ref><ref name = EMC>{{cite web|title=Arava 100mg Tablets - Summary of Product Characteristic|work=electronic Medicines Compendium|publisher=SANOFI|date=21 February 2014|accessdate=11 March 2014|url=http://www.medicines.org.uk/emc/medicine/26343/SPC/Arava+100mg+Tablets/}}</ref> diarrhea, respiratory tract infections, hair loss, [[hypertension|high blood pressure]], rash, nausea, bronchitis, headache, abdominal pain, abnormal [[liver function test]]s, back pain, [[dyspepsia|indigestion]], urinary tract infection, dizziness, infection, joint disorder, itchiness, weight loss, loss of appetite, cough, gastroenteritis, [[pharyngitis]], [[stomatitis]], [[tenosynovitis]], vomiting, weakness, allergic reaction, chest pain, dry skin, eczema, [[paraesthesia]], [[pneumonia]], [[rhinitis]], [[synovitis]], [[cholelithiasis]] and [[dyspnoea|shortness of breath]]. Whereas uncommon side effects (occurring in 0.1-1% of those treated with the drug) include:<ref name = AMH/> constipation, [[Oral candidiasis|oral thrush]], [[stomatitis]], taste disturbance, [[thrombocytopenia]] and [[urticaria|hives]]. Rarely (in 0.1% of those treated with it) it can cause:<ref name = AMH/> [[anaphylaxis]], [[angiooedema]], [[anaemia]], [[agranulocytosis]], [[eosinophilia]], [[leucopenia]], [[pancytopenia]], [[vasculitis]], [[toxic epidermal necrolysis]], [[Stevens-Johnson syndrome]], cutaneous [[lupus erythematosus]], severe infection, [[interstitial lung disease]], [[cirrhosis]] and [[liver failure]].

Though not reported elsewhere, 80 cases of [[interstitial pneumonitis]] involving leflunomide have been reported in Japan between 2003 and 2006. One such case resulting in a death was reported in a 2006 article from Japan and the authors suggest a "an inter-racial difference" for the interstitial pneumonitis.<ref>{{cite journal|last1=Hirabayashi|first1=Yu|title=Leflunomide-Induced Pneumonitis in a Patient with Rheumatoid Arthritis |journal=Internal Medicine|date=2006|volume=45|pages=689–691|issn= 1349-7235 |doi=10.2169/internalmedicine.45.1455|url=http://doi.org/10.2169/internalmedicine.45.1455|display-authors=etal}}</ref>

===Contraindications===
Contraindications include:<ref name = MSR/>
{{colbegin|3}}
* Pregnancy, women of childbearing potential (unless contraception used)
* Liver disease, [[hepatitis B]]/[[Hepatitis C|C]] seropositive
* Active serious infections
* Hypersensitivity
{{colend}}

===Interactions===
Other immunomodulatory treatments should be avoided due to the potential for additive immunosuppressant effects, or in the case of immunostimulants like [[echinacea]] or [[astragalus]], reduced therapeutic effects.<ref name = MSR/> Likewise live vaccines (like [[haemophilus influenzae type b]] vaccine and [[yellow fever]] vaccines) should be avoided due to the potential for severe infection due to the immunosuppressive nature of the treatment.<ref name = MSR/>

The concomitant use of [[methotrexate]], in particular, may lead to severe or even fatal liver-damage or hepatotoxicity. Seventy-five percent of all cases of severe liver damage reported until early 2001 were seen under combined drug therapy leflunomide plus methotrexate.<ref name = Lee/> However, some studies have shown that the combination of methotrexate and leflunomide in patients with rheumatoid arthritis gave better results than either drug alone.<ref name = Lee>{{Cite journal| last1 = Lee | first1 = S.| last2 = Park | first2 = Y.| last3 = Park | first3 = J.| last4 = Kang | first4 = Y.| last5 = Nam | first5 = E.| last6 = Kim | first6 = S.| last7 = Lee | first7 = J.| last8 = Yoo | first8 = W.| last9 = Lee | first9 = S.| title = Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis| journal = Scandinavian journal of rheumatology| volume = 38| issue = 1| pages = 11–14| year = 2009| pmid = 19191187| doi = 10.1080/03009740802360632}}</ref>

==Mechanism of action==
Leflunomide is an [[immunomodulator]]y drug that achieves its effects by inhibiting the mitochondrial enzyme [[dihydroorotate dehydrogenase]] (DHODH), which plays a key role in the ''de novo'' synthesis of [[uridine monophosphate]] (rUMP), which is required for the synthesis of DNA and RNA. Hence, leflunomide inhibits the reproduction of rapidly dividing cells, especially [[lymphocytes]].<ref name = rh2010/>

The inhibition of human DHODH by [[teriflunomide]], the active metabolite of leflunomide, occurs at levels (approximately 600 nM) that are achieved during treatment of [[rheumatoid arthritis]] (RA).<ref name = mech99/> Teriflunomide also inhibits several [[tyrosine kinases]].<ref name = rh2010/> Teriflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with their cell cycle progression while nonlymphoid cells are able to use another pathway to make their ribonucleotides by use of salvage pyrimidine pathway, which makes them less dependent on ''de novo'' synthesis.<ref name = mech99>{{cite journal|last=Fox|first=RI|author2=Herrmann, ML |author3=Frangou, CG |author4=Wahl, GM |author5=Morris, RE |author6=Strand, V |author7= Kirschbaum, BJ |title=Mechanism of action for leflunomide in rheumatoid arthritis.|journal=Clinical Immunology|date=December 1999|volume=93|issue=3|pages=198–208|doi=10.1006/clim.1999.4777|pmid=10600330}}</ref> Teriflunomide also has antiviral effects against numerous viruses including [[cytomegalovirus|CMV]], [[herpes simplex virus 1|HSV1]] and the [[BK virus]], which it achieves by inhibiting viral replication by interfering with [[nucleocapsid]] tegumentation and hence [[virion]] assembly.<ref name = rh2010/>

==Pharmacokinetics==
It has an oral bioavailability of 80%, protein binding of >99%, metabolism sites of the GI mucosa and liver, [[volume of distribution]] (V<sub>d</sub>) of 0.13 L/kg, [[elimination half-life]] of 14–18 days and excretion routes of faeces (48%) and urine (43%).<ref name = MSR/><ref name = rh2010/><ref name = TGA/>

==Leflunomide metabolism and similarity to [[teriflunomide]]==
[[Teriflunomide]] is the main active ''in vivo'' metabolite of leflunomide. Upon administration of leflunomide, 70% of the drug administered converts into teriflunomide. The only difference between the molecules is the opening of the isoxazole ring. Upon oral administration of leflunomide ''in vivo'', the isoxazole ring of leflunomide is opened and teriflunomide is formed.<ref name = "Melchiorri">{{cite web|last1=Melchiorri|first1=Daniela|last2=Barbara|first2=van Zwieten-Boot|last3=Romaldas|first3=Maciulaitis|last4=Nela|first4=Vilceanu|last5=Karsten|first5=Bruins Slot|last6=Ian|first6=Hudson|last7=Robert|first7=Hemmings|last8=Harald|first8=Enzmann|last9=Pierre|first9=Demolis|title=Assessment report. AUBAGIO (international non-proprietary name: teriflunomide). Procedure No. EMEA/H/C/002514/0000|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002514/WC500148684.pdf|website=European Medicines Agency|publisher=European Medicines Agency|accessdate=5 June 2015|archivedate=27 June 2013|page=119}}</ref>
[[File:Activation of leflunomide.svg|thumb|center|425px|'''[[Teriflunomide]]''' is the [[active metabolite]] of leflunomide, responsible for its therapeutic actions. It results from the reaction of isoxazole ring opening, which occurs ''[[in vivo]]''. Teriflunomide then can interconvert between the [[E-Z notation|''E'' and ''Z'']] [[enol]]ic forms (and the corresponding keto-amide), with the ''Z''-enol being the most stable and therefore most predominant form.<ref>{{cite journal|last1=Rozman|first1=B|title=Clinical Pharmacokinetics of Leflunomide.|journal=Clinical pharmacokinetics|date=2002|volume=41|issue=6|pages=421–30|pmid=12074690|doi=10.2165/00003088-200241060-00003}}</ref><ref>{{cite web|title=Clinical Pharmacology/Biopharmaceutics Review. Product: ARAVA (leflunomide tablets). Application Number: NDA 20905|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20905_ARAVA_BIOPHARMR.PDF|website=U.S. Food and Drug Administration|publisher=Center for Drug Evaluation and Research|accessdate=15 April 2016}}</ref>]]

"Regardless of the substance administered (leflunomide or teriflunomide), it is the same molecule (teriflunomide)—the one exerting the pharmacological, immunological or metabolic action in view of restoring, correcting or modifying physiological functions, and does not present, in clinical use, a new chemical entity to patients."<ref name = "Melchiorri" /> Because of this, [[European Medicines Agency|EMA]] initially had not considered teriflunomide being a new active substance.<ref>{{cite web|title=Summary of Opinion (Initial Authorisation): Aubagio (teriflunomide)|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002514/WC500144913.pdf|publisher=European Medicines Agency|accessdate=15 April 2016}}</ref>

==References==
{{reflist|2}}

==External links==
* [http://www.arava.com/hcp/default.aspx ARAVA<sup>®</sup> (leflunomide) 14 mg tablets] — Arava HCP website
* [http://www.nras.org.uk/about_rheumatoid_arthritis/newly_diagnosed/which_drugs_are_used/dmards_used_in_the_treatment_of_ra.aspx National Rheumatoid Arthritis Society (NRAS)] Information about Disease Modifying drugs such as Leflunomide
* http://www.rheuma-online.de/medikamente/leflunomid-arava/studien-zu-leflunomid-arava/gibt-es-untersuchungen-zu-leflunomid-in-weiteren-einsatzgebieten.html (in German, regarding potential indications)
* http://www.arznei-telegramm.de/register/0204507.pdf (in German, regarding discontinuation of the drug)
* http://www.emea.europa.eu/pdfs/human/press/pus/561101en.pdf (warning as of 2001 regarding hepatotoxicity) (URL DEAD 16 Oct 2010)
* [http://www.australianprescriber.com/magazine/36/1/28/32 The safety of leflunomide] Australian Prescriber

{{Immunosuppressants}}
{{Antirheumatic products}}

[[Category:Anilides]]
[[Category:Antirheumatic products]]
[[Category:Immunosuppressants]]
[[Category:Isoxazoles]]
[[Category:Trifluoromethyl compounds]]
[[Category:Prodrugs]]